<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02164266</url>
  </required_header>
  <id_info>
    <org_study_id>BP29205</org_study_id>
    <secondary_id>2014-000718-78</secondary_id>
    <nct_id>NCT02164266</nct_id>
  </id_info>
  <brief_title>A Study to Investigate in Healthy Volunteers (Part 1) and in Patients With Type 2 Diabetes Mellitus (Part 2) the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of RO6799477</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This study is designed to investigate the safety, tolerability, pharmacokinetics, and&#xD;
      pharmacodynamics of RO6799477 following once daily oral administration for 2 weeks in healthy&#xD;
      volunteers (Part 1) and in Type 2 diabetes patients (T2D) (Part 2). The anticipated time on&#xD;
      study treatment is two weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events (AEs)</measure>
    <time_frame>Up to 9 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters derived from plasma and urine concentrations of RO6799477, area under the concentration time curve (AUC), Cmax</measure>
    <time_frame>Day 1 and Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting serum glucose</measure>
    <time_frame>Up to 9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting serum insulin (Part 2 only)</measure>
    <time_frame>Up to 9 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy Volunteer, Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Part 1: Healthy Volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Patients with T2D, Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose daily oral administration of RO6799477</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Patients with T2D, Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose daily oral administration of RO6799477</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo daily oral administration</description>
    <arm_group_label>Part 1: Healthy Volunteers</arm_group_label>
    <arm_group_label>Part 2: Patients with T2D, Group A</arm_group_label>
    <arm_group_label>Part 2: Patients with T2D, Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO6799477</intervention_name>
    <description>Daily oral administration of RO6799477</description>
    <arm_group_label>Part 1: Healthy Volunteers</arm_group_label>
    <arm_group_label>Part 2: Patients with T2D, Group A</arm_group_label>
    <arm_group_label>Part 2: Patients with T2D, Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Part 1 Inclusion criteria:&#xD;
&#xD;
          -  Right-handed male volunteers&#xD;
&#xD;
          -  Aged 18-45 years, inclusive&#xD;
&#xD;
          -  Healthy participants, as determined by screening assessments and Principal&#xD;
             Investigator's judgment&#xD;
&#xD;
          -  Healthy status is defined by the absence of evidence of any active or chronic disease&#xD;
             following a detailed medical and surgical history, a complete physical examination&#xD;
             including vital signs, 12-lead ECG, hematology, blood chemistry, serology and&#xD;
             urinalysis&#xD;
&#xD;
          -  Body Mass Index (BMI) of 18-30 kg/m2 inclusive, with body weight in the range of&#xD;
             50-100 kg&#xD;
&#xD;
        Part 2 Inclusion Criteria:&#xD;
&#xD;
          -  Patients with type 2 diabetes according to WHO criteria diagnosed for at least 3&#xD;
             months prior to screening&#xD;
&#xD;
          -  Male or female patients, 40 to 65 years of age, inclusive&#xD;
&#xD;
          -  Type 2 diabetic patients who are either drug naive (diet &amp; exercise alone) or on a&#xD;
             stable dose of metformin for at least 3 months prior to screening or willing to safely&#xD;
             stop sulfonylurea medications at least 2 weeks prior to first dose administration and&#xD;
             until follow-up visit&#xD;
&#xD;
          -  BMI of 23-42 kg/m2, inclusive&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Part 1 Exclusion criteria:&#xD;
&#xD;
          -  Any clinically relevant history or the presence of e.g. respiratory, renal, hepatic,&#xD;
             gastrointestinal, hematological, lymphatic, neurological, cardiovascular, psychiatric,&#xD;
             etc. disease or diseases&#xD;
&#xD;
          -  Disorders of central nervous system, psychiatric disorders, behavioral disturbances&#xD;
             (e.g. cerebrovascular events, depression, post-traumatic stress disorder [PTSD],&#xD;
             anxiety, bipolar disorder, severe migraine, Parkinson's disease)&#xD;
&#xD;
          -  Participation in an investigational drug or device study within 3 months prior to&#xD;
             screening or more than 4 times per year&#xD;
&#xD;
          -  Concomitant disease or condition that could interfere with, or treatment of which&#xD;
             might interfere with, the conduct of the study, or that would, in the opinion of the&#xD;
             investigator, pose an unacceptable risk to the subject in this study&#xD;
&#xD;
        Part 2 Exclusion Criteria:&#xD;
&#xD;
          -  Type 1 diabetes&#xD;
&#xD;
          -  Acquired or secondary forms of diabetes such as those resulting from pancreatic&#xD;
             surgery/injury, cystic fibrosis related diabetes&#xD;
&#xD;
          -  Evidence or history of clinically significant diabetic complications such as&#xD;
             clinically severe diabetic peripheral neuropathy, clinically significant nephropathy&#xD;
             as judged by the investigator, or pre-proliferative/proliferative diabetic retinopathy&#xD;
             as judged by the investigator or already diagnosed by the diabetologist or general&#xD;
             practitioner&#xD;
&#xD;
          -  Disorders of central nervous system, psychiatric disorders, behavioral disturbances&#xD;
&#xD;
          -  Clinically significant history or presence of bronchopulmonary, gastrointestinal,&#xD;
             hematological, lymphatic, neurological, psychiatric, musculoskeletal, genitourinary,&#xD;
             immunological, dermatological, infectious, connective tissue or inflammatory diseases,&#xD;
             and any type of cancer (with the exception of treated basal cell carcinoma of the&#xD;
             skin) or other clinically significant disease&#xD;
&#xD;
          -  Use of anti-diabetic drugs other than metformin or sulfonylureas within 2 months prior&#xD;
             to screening&#xD;
&#xD;
          -  Any condition or disease detected during the medical interview / physical examination&#xD;
             that would render the patient unsuitable for the study, place the patient at undue&#xD;
             risk or interfere with the ability of the patient to complete the study in the opinion&#xD;
             of the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Leiden</city>
        <zip>2333</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>June 6, 2014</study_first_submitted>
  <study_first_submitted_qc>June 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2014</study_first_posted>
  <last_update_submitted>June 13, 2017</last_update_submitted>
  <last_update_submitted_qc>June 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

